Bioqual (BIOQ) Aktsia Kursus
Bioqual Kursus
Käive kasvas 4,1 % aastas viimase 22 aasta jooksul 39,95 M USD-ni. Kasum aktsia kohta langes 1,7 % aastas viimase 20 aasta jooksul. Bioqual netomarginaal on nüüd −10,4 %, langenud 8,0 %-lt mõni aasta tagasi. Bioqual pakub praegu umbes 1,61 % dividenditootlust. Väljamaksesuhe on umbes 54 % kasumist. Dividend kasvas 8,3 % aastas viimase 19 aasta jooksul.
Bioqual aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Bioqual ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Bioqual aktsia kohta
The business model of Bioqual Inc is to provide contract research services to biotechnology and pharmaceutical companies, government agencies, and academic institutions. Bioqual specializes in preclinical and clinical research, including animal model development, in vitro testing, and regulatory compliance. Through collaboration with clients, Bioqual aims to advance the development of drugs, vaccines, and therapeutics, ultimately contributing to the improvement of human and animal health. With its expertise and state-of-the-art facilities, Bioqual Inc has established itself as a trusted partner in the biomedical research industry.
Bioqual Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Bioqual Inc in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services to Bioqual Inc. Their competitive presence challenges Bioqual Inc's market position and drives innovation within the industry. Maintaining a competitive edge is crucial for Bioqual Inc to attract and retain customers, expand its market share, and achieve long-term success. As Bioqual Inc continues to navigate its way in the market, it recognizes the importance of monitoring and adapting to the strategies and offerings of its key competitors.
Bioqual Inc. is a reputable company with a rich history and background. Established in [year], Bioqual Inc. has been a leading player in the [industry] sector. The company specializes in [specific products/services] and has built a strong reputation for its commitment to innovation, quality, and customer satisfaction. With a team of experienced professionals and state-of-the-art facilities, Bioqual Inc. has consistently delivered outstanding results and garnered recognition for its contributions to [industry]. Over the years, Bioqual Inc. has expanded its presence globally and continues to be a trusted name in the [industry] market, providing sustainable solutions and driving advancements in [industry].
Bioqual Inc has achieved several significant milestones over the years. The company has successfully gained recognition as a leading biomedical research organization, specializing in preclinical and clinical testing services. Notably, Bioqual Inc has garnered a strong reputation for its contributions to drug development, infectious disease research, and vaccine testing. The company has also established numerous strategic partnerships with pharmaceutical and biotech companies, academia, and government agencies. Furthermore, Bioqual Inc has consistently demonstrated exceptional scientific expertise, state-of-the-art facilities, and a commitment to quality, making it a trusted name in the industry.
Bioqual Inc is primarily present in the United States.
Bioqual Inc represents a commitment to excellence in the field of biomedical research. With a strong emphasis on animal modeling and preclinical testing services, Bioqual is dedicated to paving the way for breakthrough discoveries in healthcare and life sciences. The company's corporate philosophy revolves around comprehensive expertise, innovative solutions, and ensuring the highest standards of animal welfare. By providing state-of-the-art facilities and a team of skilled professionals, Bioqual strives to support scientific advancements and contribute to the development of novel therapies and vaccines. With a focus on quality, reliability, and integrity, Bioqual Inc is trusted by leading pharmaceutical and biotechnology companies worldwide.
Praeguse kursiga kaubeldakse Bioqual aktsiaga 27,78 EUR (31,00 USD) juures.
Bioqual Inc is a US-based company specializing in providing research services and products for the life sciences, pharmaceuticals, and biotechnology industries. The company was founded in 1981 and has been offering innovative solutions to its customers since then.
Bioqual käive on 39,95 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
Bioqual kasum on −4,17 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Bioqual jaoks on praegu −6,65. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Bioqual aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Bioqual jaoks on praegu 0,69. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Bioqual aktsia jaoks.
Eulpooli kvaliteedinäitaja Bioqual jaoks on 1/10.
Bioqual ISIN on US09065J1016. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Bioqual ticker on BIOQ. Ticker-sümbol kasutatakse Bioqual aktsiate kauplemiseks börsil.
Bioqual aktsia
Bioqual konkurendid
Bioqual FIGI
Kõik teised näitajad ja analüüsid Bioqual kohta sügavamalt
Meie Bioqual-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Bioqual. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: